Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

2013460 citationsJournal Articlegreen Open Access

Authors

Ana M. Aparicio · University of California, San Francisco

Andrea Harzstark · University of California, San Francisco

Paul G. Corn · University of California, San Francisco

Sijin Wen · The University of Texas MD Anderson Cancer Center

John C. Araujo · The University of Texas MD Anderson Cancer Center

Shi‐Ming Tu · UCSF Helen Diller Family Comprehensive Cancer Center

Lance C. Pagliaro

Abstract

Our findings support the hypothesis that patients with "anaplastic" prostate cancer are a recognizable subset characterized by a high response rate of short duration to platinum-containing chemotherapies, similar to SCPC. Our results suggest that CEA is useful for selecting therapy in men with castration-resistant prostate cancer and consolidative therapies to bulky high-grade tumor masses should be considered in this patient population.

Topics & Keywords

Prostate Cancer Treatment and Research Peptidase Inhibition and Analysis Multiple Myeloma Research and Treatments

Publication Details

Published in: Clinical Cancer Research

Volume 19, Issue 13, pp. 3621-3630

DOI: 10.1158/1078-0432.ccr-12-3791

Field-Weighted Citation Impact: 21.32

Command Palette

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details